| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2007Sci...316.1628M |
| P356 | DOI | 10.1126/SCIENCE.1138963 |
| P698 | PubMed publication ID | 17569868 |
| P5875 | ResearchGate publication ID | 6267089 |
| P50 | author | Paula Chilton | Q54768233 |
| Verónica Mata-Haro | Q56438089 | ||
| P2093 | author name string | Michael Martin | |
| Thomas C Mitchell | |||
| Caglar Cekic | |||
| Carolyn R Casella | |||
| P433 | issue | 5831 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| bias | Q742736 | ||
| toll-like receptor | Q408004 | ||
| P304 | page(s) | 1628-1632 | |
| P577 | publication date | 2007-06-01 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. | |
| P478 | volume | 316 |
| Q34520389 | A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity |
| Q42758965 | A Light-Controlled TLR4 Agonist and Selectable Activation of Cell Subpopulations |
| Q40649527 | A Lipid Based Antigen Delivery System Efficiently Facilitates MHC Class-I Antigen Presentation in Dendritic Cells to Stimulate CD8(+) T Cells |
| Q30145658 | A Novel Agonist of the TRIF Pathway Induces a Cellular State Refractory to Replication of Zika, Chikungunya, and Dengue Viruses |
| Q36162709 | A Novel Class of Small Molecule Agonists with Preference for Human over Mouse TLR4 Activation |
| Q35757125 | A Novel Prime and Boost Regimen of HIV Virus-Like Particles with TLR4 Adjuvant MPLA Induces Th1 Oriented Immune Responses against HIV. |
| Q97420803 | A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity |
| Q48196685 | A Semisynthetic Approach to New Immunoadjuvant Candidates: Site-Selective Chemical Manipulation of Escherichia coli Monophosphoryl Lipid A. |
| Q59137480 | A Strong Humoral Immune Response Induced by a Vaccine Formulation Containing rSm29 Adsorbed to Alum Is Associated With Protection Against Reinfection in Mice |
| Q35990046 | A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses |
| Q38983228 | A combined fermentative-chemical approach for the scalable production of pure E. coli monophosphoryl lipid A. |
| Q34755217 | A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy |
| Q88964571 | A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model |
| Q21089976 | A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine |
| Q39711054 | A molecular mechanism for Toll-IL-1 receptor domain-containing adaptor molecule-1-mediated IRF-3 activation |
| Q36452968 | A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo |
| Q56794150 | A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems |
| Q33954369 | A role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteins |
| Q28818147 | A structure-function approach to optimizing TLR4 ligands for human vaccines |
| Q37529419 | Acellular and "low" pertussis vaccines: adverse events and the role of mutations |
| Q92092569 | Activation of STAT3 is a key event in TLR4 signaling-mediated melanoma progression |
| Q33601866 | Activation of innate immune responses by Haemophilus influenzae lipooligosaccharide |
| Q37123782 | Adjuvant activity of naturally occurring monophosphoryl lipopolysaccharide preparations from mucosa-associated bacteria |
| Q38096056 | Adjuvant immunotherapies as a novel approach to bacterial infections |
| Q34920323 | Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation |
| Q38264288 | Adjuvants and delivery systems for antifungal vaccines: current state and future developments |
| Q38124063 | Adjuvants containing natural and synthetic Toll-like receptor 4 ligands |
| Q37873932 | Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. |
| Q35826747 | Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators |
| Q26747586 | Adjuvants: Classification, Modus Operandi, and Licensing |
| Q36035019 | Adsorption of Toll-Like Receptor 4 Agonist to Alum-Based Tetanus Toxoid Vaccine Dampens Pro-T Helper 2 Activities and Enhances Antibody Responses |
| Q35536407 | Alkaline phosphatase protects lipopolysaccharide-induced early pregnancy defects in mice |
| Q87450793 | Allergen ligands in the initiation of allergic sensitization |
| Q49592130 | Aminosugar-based immunomodulator lipid A: synthetic approaches |
| Q33724967 | An inactivated hand-foot-and-mouth disease vaccine using the enterovirus 71 (C4a) strain isolated from a Korean patient induces a strong immunogenic response in mice. |
| Q40485597 | An inflammatory response is essential for the development of adaptive immunity-immunogenicity and immunotoxicity |
| Q92462186 | Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants |
| Q35995535 | Antimicrobial aspects of inflammatory resolution in the mucosa: a role for proresolving mediators |
| Q38123937 | Applications of nanotechnology for immunology |
| Q39780595 | Artificial bacterial biomimetic nanoparticles synergize pathogen-associated molecular patterns for vaccine efficacy |
| Q89509471 | Avian Pattern Recognition Receptor Sensing and Signaling |
| Q79914766 | Bacterial cell walls, innate immunity and immunoadjuvants |
| Q26824573 | Beyond empiricism: informing vaccine development through innate immunity research |
| Q34345012 | Biomaterials for nanoparticle vaccine delivery systems |
| Q47641212 | Biosynthesis and structure-activity relationships of the lipid a family of glycolipids |
| Q38386726 | Biosynthetically engineered lipopolysaccharide as vaccine adjuvant |
| Q41359748 | Bordetella pertussis Lipid A Recognition by Toll-like Receptor 4 and MD-2 Is Dependent on Distinct Charged and Uncharged Interfaces |
| Q30376493 | Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice. |
| Q27014949 | CD4(+) T Cell Priming as Biomarker to Study Immune Response to Preventive Vaccines |
| Q34501441 | CD83 increases MHC II and CD86 on dendritic cells by opposing IL-10-driven MARCH1-mediated ubiquitination and degradation. |
| Q34694992 | Campylobacter jejuni lipooligosaccharide sialylation, phosphorylation, and amide/ester linkage modifications fine-tune human Toll-like receptor 4 activation |
| Q37701353 | Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery |
| Q94465687 | Carbohydrate Conjugates in Vaccine Developments |
| Q35088222 | Characterization of TRIF selectivity in the AGP class of lipid A mimetics: role of secondary lipid chains. |
| Q36738797 | Characterization of cross protection of Swine-Origin Influenza Virus (S-OIV) H1N1 and reassortant H5N1 influenza vaccine in BALB/c mice given a single-dose vaccination |
| Q28538989 | Characterization of the structure and immunostimulatory activity of a vaccine adjuvant, de-O-acylated lipooligosaccharide |
| Q33714195 | Chemical synthesis and proinflammatory responses of monophosphoryl lipid A adjuvant candidates |
| Q33826107 | Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive |
| Q41684063 | Co-delivery of Dual Toll-Like Receptor Agonists and Antigen in Poly(Lactic-Co-Glycolic) Acid/Polyethylenimine Cationic Hybrid Nanoparticles Promote Efficient In Vivo Immune Responses. |
| Q50080885 | Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma |
| Q57835957 | Colloidal characteristics and formulation of pure protein particulate vaccines |
| Q48507691 | Combination therapy with proteasome inhibitors and TLR agonists enhances tumour cell death and IL-1β production. |
| Q33746872 | Combinatorial Delivery of Dual and Triple TLR Agonists via Polymeric Pathogen-like Particles Synergistically Enhances Innate and Adaptive Immune Responses |
| Q27304818 | Combining cationic liposomal delivery with MPL-TDM for cysteine protease cocktail vaccination against Leishmania donovani: evidence for antigen synergy and protection |
| Q37560510 | Comparative Transcriptome Profiles of Human Blood in Response to the Toll-like Receptor 4 Ligands Lipopolysaccharide and Monophosphoryl Lipid A. |
| Q35862009 | Comparison of Gene Expression by Sheep and Human Blood Stimulated with the TLR4 Agonists Lipopolysaccharide and Monophosphoryl Lipid A. |
| Q37692880 | Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer |
| Q36801478 | Comparison of the immunostimulatory and proinflammatory activities of candidate Gram-positive endotoxins, lipoteichoic acid, peptidoglycan, and lipopeptides, in murine and human cells |
| Q50044074 | Construction of an Escherichia coli mutant producing monophosphoryl lipid A. |
| Q36806692 | Construction of monophosphoryl lipid A producing Escherichia coli mutants and comparison of immuno-stimulatory activities of their lipopolysaccharides |
| Q37780267 | Contribution of Porphyromonas gingivalis lipopolysaccharide to periodontitis |
| Q42204833 | Contribution of TLR4 and MyD88 for adjuvant monophosphoryl lipid A (MPLA) activity in a DNA prime-protein boost HIV-1 vaccine |
| Q26829061 | Contribution of Toll-like receptor signaling to germinal center antibody responses |
| Q33719500 | Contributions of neutrophils to resolution of mucosal inflammation |
| Q27318446 | CpG-ODN and MPLA prevent mortality in a murine model of post-hemorrhage-Staphyloccocus aureus pneumonia |
| Q86763009 | Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo |
| Q90631779 | Dendritic Cell Membrane Vesicles for Activation and Maintenance of Antigen-Specific T Cells |
| Q37273249 | Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant |
| Q34074750 | Design of lipid nanocapsule delivery vehicles for multivalent display of recombinant Env trimers in HIV vaccination |
| Q58998287 | Destructive role of myeloid differentiation factor 88 and protective role of TRIF in interleukin-17-dependent arthritis in mice |
| Q21091066 | Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant |
| Q45716103 | Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors. |
| Q54943714 | Development of a vaccine based on bacteria-mimicking tumor cells coated with novel engineered toll-like receptor 2 ligands. |
| Q34631422 | Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach |
| Q39994959 | DiC14-amidine cationic liposomes stimulate myeloid dendritic cells through Toll-like receptor 4. |
| Q37971120 | Different dimerisation mode for TLR4 upon endosomal acidification? |
| Q87233115 | Differential IL-10 production by DCs determines the distinct adjuvant effects of LPS and PTX in EAE induction |
| Q33784386 | Differential effect of TLR2 and TLR4 on the immune response after immunization with a vaccine against Neisseria meningitidis or Bordetella pertussis |
| Q39852234 | Differential expression of immunoregulatory genes in monocytes in response to Porphyromonas gingivalis and Escherichia coli lipopolysaccharide. |
| Q34121591 | Differential induction of innate immune responses by synthetic lipid a derivatives |
| Q36300342 | Differential outcome of TRIF-mediated signaling in TLR4 and TLR3 induced DC maturation |
| Q38201155 | Directing the immune system with chemical compounds |
| Q94600957 | Dissociation of TRIF bias and adjuvanticity |
| Q47143691 | Distinct Effects of Monophosphoryl Lipid A, Oligodeoxynucleotide CpG, and Combination Adjuvants on Modulating Innate and Adaptive Immune Responses to Influenza Vaccination |
| Q35849215 | Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates |
| Q37627725 | Distinct pathways of humoral and cellular immunity induced with the mucosal administration of a nanoemulsion adjuvant. |
| Q88493495 | Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy |
| Q38108059 | Dynamic regulation of Bcl6 in follicular helper CD4 T (Tfh) cells |
| Q36787810 | Dysregulation of human Toll-like receptor function in aging |
| Q34258820 | Educating CD4 T cells with vaccine adjuvants: lessons from lipopolysaccharide |
| Q45350204 | Effect of Toll-like receptor 4 blockade on pulmonary inflammation caused by mechanical ventilation and bacterial endotoxin |
| Q36029323 | Effects of Differences in Lipid A Structure on TLR4 Pro-Inflammatory Signaling and Inflammasome Activation. |
| Q34973787 | Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy |
| Q44960684 | Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats |
| Q36552355 | Endothelial cell tolerance to lipopolysaccharide challenge is induced by monophosphoryl lipid A. |
| Q36357406 | Energetics of Endotoxin Recognition in the Toll-Like Receptor 4 Innate Immune Response |
| Q33927138 | Enhancement of tumor-specific T cell-mediated immunity in dendritic cell-based vaccines by Mycobacterium tuberculosis heat shock protein X. |
| Q38825526 | Epigenetic Modifications of Histones in Periodontal Disease. |
| Q41956528 | Escherichia coli mutants that synthesize dephosphorylated lipid A molecules. |
| Q42929847 | Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants |
| Q33511964 | Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice |
| Q42705186 | Expression level of human TLR4 rather than sequence is the key determinant of LPS responsiveness |
| Q39219558 | Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice |
| Q52356828 | Formulation in DDA-MPLA-TDB Liposome Enhances the Immunogenicity and Protective Efficacy of a DNA Vaccine against Mycobacterium tuberculosis Infection. |
| Q38113080 | Fortifying the barrier: the impact of lipid A remodelling on bacterial pathogenesis. |
| Q37837477 | From vaccine practice to vaccine science: the contribution of human immunology to the prevention of infectious disease |
| Q36850638 | Fully Synthetic Self-Adjuvanting α-2,9-Oligosialic Acid Based Conjugate Vaccines against Group C Meningitis |
| Q46329132 | Funiculosin variants and phosphorylated derivatives promote innate immune responses via the Toll-like receptor 4/myeloid differentiation factor-2 complex. |
| Q35886513 | Gene expression profiles identify both MyD88-independent and MyD88-dependent pathways involved in the maturation of dendritic cells mediated by heparan sulfate: a novel adjuvant |
| Q41180997 | Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. |
| Q35228094 | Genome-wide expression profiling and mutagenesis studies reveal that lipopolysaccharide responsiveness appears to be absolutely dependent on TLR4 and MD-2 expression and is dependent upon intermolecular ionic interactions |
| Q33388690 | HIV-1 activates macrophages independent of Toll-like receptors |
| Q38218093 | Heme on innate immunity and inflammation |
| Q34823577 | Host inactivation of bacterial lipopolysaccharide prevents prolonged tolerance following gram-negative bacterial infection |
| Q39282348 | Human TLR4 polymorphism D299G/T399I alters TLR4/MD-2 conformation and response to a weak ligand monophosphoryl lipid A. |
| Q36990637 | Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses |
| Q24321459 | Human parotid secretory protein is a lipopolysaccharide-binding protein: identification of an anti-inflammatory peptide domain |
| Q34446653 | Humanized TLR4/MD-2 mice reveal LPS recognition differentially impacts susceptibility to Yersinia pestis and Salmonella enterica |
| Q30388683 | Identification of Adjuvantic Activity of Amphotericin B in a Novel, Multiplexed, Poly-TLR/NLR High-Throughput Screen |
| Q30371303 | Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. |
| Q37043647 | Identification of substituted pyrimido[5,4-b]indoles as selective Toll-like receptor 4 ligands |
| Q42746157 | Imbalance of Clara cell-mediated homeostatic inflammation is involved in lung metastasis. |
| Q28972540 | Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands |
| Q51141205 | Immune activation with peptide assemblies carrying Lewis y tumor-associated carbohydrate antigen. |
| Q46431958 | Immune cells and oxidative stress in the endotoxin tolerance mouse model |
| Q36933839 | Immune response to ORF5a protein immunization is not protective against porcine reproductive and respiratory syndrome virus infection. |
| Q27016633 | Immune response to vaccine adjuvants during the first year of life |
| Q36826344 | Immunization with pneumococcal polysaccharide serotype 3 and lipopolysaccharide modulates lung and liver inflammation during a virulent Streptococcus pneumoniae infection in mice |
| Q35879700 | Immuno-Stimulatory Activity of Escherichia coli Mutants Producing Kdo2-Monophosphoryl-Lipid A or Kdo2-Pentaacyl-Monophosphoryl-Lipid A. |
| Q35887180 | Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine |
| Q40497346 | Immunogenicity and protective efficacy of recombinant iron superoxide dismutase protein from Bordetella pertussis in mice models |
| Q35659533 | Immunological mechanisms of vaccination |
| Q38749164 | Immunosenescence of microglia and macrophages: impact on the ageing central nervous system. |
| Q38836832 | Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression |
| Q99550506 | Impact of the intestinal environment on the immune responses to vaccination |
| Q52887434 | Improved vaccines through targeted manipulation of the body's immunological risk-assessment? |
| Q51151392 | Improvement of Peptide-Based Tumor Immunotherapy Using pH-Sensitive Fusogenic Polymer-Modified Liposomes. |
| Q92069078 | In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors |
| Q58553701 | In vivo cancer vaccination: Which dendritic cells to target and how? |
| Q30373740 | Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity. |
| Q58827790 | Incorporation of the TLR4 Agonist Monophosphoryl Lipid A Into the Bilayer of DDA/TDB Liposomes: Physico-Chemical Characterization and Induction of CD8+ T-Cell Responses In Vivo |
| Q35548034 | Induction of potent adaptive immunity by the novel polyion complex nanoparticles |
| Q34701875 | Inefficient TLR4/MD-2 heterotetramerization by monophosphoryl lipid A |
| Q99708844 | Inflammasome-Mediated Immunogenicity of Clinical and Experimental Vaccine Adjuvants |
| Q42193505 | Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice. |
| Q34026949 | Influence of genetic variations in TLR4 and TIRAP/Mal on the course of sepsis and pneumonia and cytokine release: an observational study in three cohorts |
| Q34996712 | Influence of lipid A acylation pattern on membrane permeability and innate immune stimulation |
| Q33903025 | Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression |
| Q37280601 | Innate Immunity in the Female Reproductive Tract: Role of Sex Hormones in Regulating Uterine Epithelial Cell Protection Against Pathogens |
| Q40245353 | Innate immune response to lipooligosaccharide: pivotal regulator of the pathobiology of invasive Neisseria meningitidis infections. |
| Q36215126 | Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model |
| Q38053641 | Interactions between LPS moieties and macrophage pattern recognition receptors |
| Q34802680 | Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses |
| Q38216206 | Interferon regulatory factor 3 in adaptive immune responses. |
| Q37707264 | Intestinal dendritic cells: their role in bacterial recognition, lymphocyte homing, and intestinal inflammation |
| Q34850331 | Intracellular delivery of lipopolysaccharide induces effective Th1-immune responses independent of IL-12. |
| Q34309830 | Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives. |
| Q38461061 | Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies |
| Q35468441 | Kdo2 -lipid A: structural diversity and impact on immunopharmacology |
| Q41584736 | Lack of lipid A pyrophosphorylation and functional lptA reduces inflammation by Neisseria commensals |
| Q34046148 | Laser vaccine adjuvant for cutaneous immunization |
| Q46787046 | Lipid A and liposomes containing lipid A as antigens and adjuvants |
| Q45852371 | Lipid A from lipopolysaccharide recognition: structure, dynamics and cooperativity by molecular dynamics simulations. |
| Q36960814 | Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine |
| Q39096977 | Lipid A structural modifications in extreme conditions and identification of unique modifying enzymes to define the Toll-like receptor 4 structure-activity relationship |
| Q89739210 | Lipopolysaccharide Reverses Hepatic Stellate Cell Activation via Modulation of cMyb, SMADs and C/EBP Transcription Factors |
| Q37653359 | Lipopolysaccharide engineering in Neisseria meningitidis: structural analysis of different pentaacyl lipid A mutants and comparison of their modified agonist properties |
| Q34164779 | Lipopolysaccharide potentiates effector T cell accumulation into nonlymphoid tissues through TRIF |
| Q34658112 | Liposomal lipopolysaccharide initiates TRIF-dependent signaling pathway independent of CD14. |
| Q99247025 | Live attenuated Salmonella enterica serovar Choleraesuis vector delivering a conserved surface protein enolase induces high and broad protection against Streptococcus suis serotypes 2, 7, and 9 in mice |
| Q61058428 | Local cytokine and inflammatory responses to candidate vaginal adjuvants in mice |
| Q55073266 | MPLA inhibits release of cytotoxic mediators from human neutrophils while preserving efficient bacterial killing. |
| Q41156645 | MPLA shows attenuated pro-inflammatory properties and diminished capacity to activate mast cells in comparison with LPS. |
| Q37045743 | Macrophage activation by endogenous danger signals |
| Q40093877 | Mechanism of impaired NLRP3 inflammasome priming by monophosphoryl lipid A. |
| Q90169837 | Membrane TLR9 Positive Neutrophil Mediated MPLA Protects Against Fatal Bacterial Sepsis |
| Q37735277 | Memory T-cell trafficking: new directions for busy commuters. |
| Q91579137 | Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development |
| Q38073752 | Modern subunit vaccines: development, components, and research opportunities |
| Q36513466 | Modification of the 1-Phosphate Group during Biosynthesis of Capnocytophaga canimorsus Lipid A. |
| Q35737359 | Modulating LPS signal transduction at the LPS receptor complex with synthetic Lipid A analogues |
| Q40453387 | Modulating endotoxin activity by combinatorial bioengineering of meningococcal lipopolysaccharide. |
| Q34321369 | Modulating the innate immune response by combinatorial engineering of endotoxin |
| Q37342800 | Modulation of Primary Immune Response by Different Vaccine Adjuvants |
| Q36980608 | Modulation of adaptive immunity by different adjuvant-antigen combinations in mice lacking Nod2. |
| Q39985578 | Modulation of immunoproteasome subunits by liposomal lipid A. |
| Q64097188 | Molecular mechanisms in progression of HPV-associated cervical carcinogenesis |
| Q90065722 | Monophosphoryl lipid A alleviated radiation-induced testicular injury through TLR4-dependent exosomes |
| Q62589991 | Monophosphoryl lipid A coating of hydroxyethyl starch nanocapsules drastically increases uptake and maturation by dendritic cells while minimizing the adjuvant dosage |
| Q40273214 | Monophosphoryl lipid A induces protection against LPS in medullary thick ascending limb through a TLR4-TRIF-PI3K signaling pathway |
| Q35779592 | Monophosphoryl lipid A inhibits the cytokine response of endothelial cells challenged with LPS. |
| Q45733638 | Monophosphoryl lipid A is an lipopolysaccharide-derived Toll-like receptor 4 agonist which may improve Alzheimer's disease pathology |
| Q88612161 | Monophosphoryl lipid A prevents impairment of medullary thick ascending limb [Formula: see text] absorption and improves plasma [Formula: see text] concentration in septic mice |
| Q52879746 | Monophosphoryl lipid A-induced pro-inflammatory cytokine expression does not require CD14 in primary human dendritic cells. |
| Q47134893 | Monophosphoryl lipid a attenuates radiation injury through TLR4 activation |
| Q34722855 | Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice |
| Q87087763 | Multifunctional liposomes constituting microneedles induced robust systemic and mucosal immunoresponses against the loaded antigens via oral mucosal vaccination |
| Q37197084 | Multifunctional particle-constituted microneedle arrays as cutaneous or mucosal vaccine adjuvant-delivery systems |
| Q27008380 | Multiple roles of toll-like receptor 4 in colorectal cancer |
| Q30392924 | Multistrain influenza protection induced by a nanoparticulate mucosal immunotherapeutic |
| Q37243896 | MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant |
| Q33776975 | MyD88 signaling is not essential for induction of antigen-specific B cell responses but is indispensable for protection against Streptococcus pneumoniae infection following oral vaccination with attenuated Salmonella expressing PspA antigen |
| Q35644967 | MyD88-dependent SHIP1 regulates proinflammatory signaling pathways in dendritic cells after monophosphoryl lipid A stimulation of TLR4. |
| Q95831756 | Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics |
| Q92733975 | Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity |
| Q50531820 | Nanoparticle-Fusion Protein Complexes Protect against Mycobacterium tuberculosis Infection. |
| Q33468766 | Natural phosphoryl and acyl variants of lipid A from Neisseria meningitidis strain 89I differentially induce tumor necrosis factor-alpha in human monocytes |
| Q43753943 | Naturally occurring low biological reactivity lipopolysaccharides as vaccine adjuvants |
| Q36653379 | New technologies in developing recombinant attenuated Salmonella vaccine vectors |
| Q34999938 | Novel drugs targeting Toll-like receptors for antiviral therapy |
| Q37763270 | Novel strategies for the prevention and treatment of Candida infections: the potential of immunotherapy |
| Q35406737 | Novel strategies to fight Candida species infection. |
| Q33944008 | Novel synthetic toll-like receptor 4/MD2 ligands attenuate sterile inflammation |
| Q33713662 | Of microbes and meals: the health consequences of dietary endotoxemia. |
| Q51041005 | Optimal CD4 T cell priming after LPS-based adjuvanticity with CD134 costimulation relies on CXCL9 production. |
| Q94451631 | Optimization of an Experimental Vaccine To Prevent Escherichia coli Urinary Tract Infection |
| Q26766539 | Outer membrane vesicles as platform vaccine technology |
| Q64106847 | Ovalbumin Epitope SIINFEKL Self-Assembles into a Supramolecular Hydrogel |
| Q39957984 | Paclitaxel binding to human and murine MD-2. |
| Q36565162 | Paediatric obstructive sleep apnoea syndrome (OSAS) is associated with tonsil colonisation by Streptococcus pyogenes |
| Q54230568 | Parenterally Administered Norovirus GII.4 Virus-Like Particle Vaccine Formulated with Aluminum Hydroxide or Monophosphoryl Lipid A Adjuvants Induces Systemic but Not Mucosal Immune Responses in Mice. |
| Q38286377 | Particulate inorganic adjuvants: recent developments and future outlook |
| Q39070506 | Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells |
| Q24643034 | Pathogen recognition and inflammatory signaling in innate immune defenses |
| Q37981769 | Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants |
| Q57157844 | Personalized vaccines: the emerging field of vaccinomics |
| Q45272225 | Pharmaceutical sciences in 2020. |
| Q36599638 | Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4 |
| Q36506184 | Phosphoethanolamine residues on the lipid A moiety of Neisseria gonorrhoeae lipooligosaccharide modulate binding of complement inhibitors and resistance to complement killing |
| Q34690369 | Phosphoryl moieties of lipid A from Neisseria meningitidis and N. gonorrhoeae lipooligosaccharides play an important role in activation of both MyD88- and TRIF-dependent TLR4-MD-2 signaling pathways |
| Q34281691 | Pivotal advance: The pattern recognition receptor ligands lipopolysaccharide and polyinosine-polycytidylic acid stimulate factor B synthesis by the macrophage through distinct but overlapping mechanisms |
| Q64093079 | Poly(I:C) Potentiates T Cell Immunity to a Dendritic Cell Targeted HIV-Multiepitope Vaccine |
| Q33942532 | Potent intestinal Th17 priming through peripheral lipopolysaccharide-based immunization |
| Q89739777 | Potential microglia-based interventions for stroke |
| Q82738285 | Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations |
| Q58842209 | Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of Trypanosoma cruzi infection in mice |
| Q30400144 | Programming the magnitude and persistence of antibody responses with innate immunity |
| Q37259642 | Promising particle-based vaccines in cancer therapy. |
| Q34182445 | Promoting tolerance to proteolipid protein-induced experimental autoimmune encephalomyelitis through targeting dendritic cells |
| Q37989884 | Prophylactic and therapeutic implications of toll-like receptor ligands |
| Q38089935 | Prostate cancer vaccines. |
| Q37032632 | Protective cancer immunotherapy: what can the innate immune system contribute? |
| Q37109519 | Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant |
| Q41921233 | Quantifying the relative immune cell activation from whole tissue/organ-derived differentially expressed gene data |
| Q39712533 | Quantum dots decorated with pathogen associated molecular patterns as fluorescent synthetic pathogen models |
| Q33790424 | RNA and imidazoquinolines are sensed by distinct TLR7/8 ectodomain sites resulting in functionally disparate signaling events |
| Q37061815 | RNA is an Adjuvanticity Mediator for the Lipid-Based Mucosal Adjuvant, Endocine |
| Q45074067 | Rational incorporation of molecular adjuvants into a hybrid nanoparticle-based nicotine vaccine for immunotherapy against nicotine addiction |
| Q34493434 | Rationally Designed Macrocyclic Peptides as Synergistic Agonists of LPS-Induced Inflammatory Response |
| Q38081375 | Recognition of lipid A variants by the TLR4-MD-2 receptor complex |
| Q24622138 | Recognition of lipopolysaccharide pattern by TLR4 complexes |
| Q90743890 | Recombinant flagellins with deletions in domains D1, D2, and D3: Characterization as novel immunoadjuvants |
| Q38047077 | Regulators of innate immunity as novel targets for panviral therapeutics |
| Q36968256 | Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation |
| Q37392081 | Requirement of TLR4 and CD14 in dendritic cell activation by Hemagglutinin B from Porphyromonas gingivalis |
| Q37714634 | Responses to LPS boost effector CD8 T-cell accumulation outside of signals 1 and 2. |
| Q38201040 | Reviewing and identifying amino acids of human, murine, canine and equine TLR4 / MD-2 receptor complexes conferring endotoxic innate immunity activation by LPS/lipid A, or antagonistic effects by Eritoran, in contrast to species-dependent modulation |
| Q36676013 | Role of G-CSF in monophosphoryl lipid A-mediated augmentation of neutrophil functions after burn injury. |
| Q30424747 | Role of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge |
| Q26777264 | Roles and relevance of mast cells in infection and vaccination |
| Q38039958 | Roles of toll-like receptors in cancer: a double-edged sword for defense and offense |
| Q99237974 | S100A8 and S100A9 Promote Apoptosis of Chronic Eosinophilic Leukemia Cells |
| Q42186082 | SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines |
| Q52611929 | SAMHD1 suppresses innate immune responses to viral infections and inflammatory stimuli by inhibiting the NF-κB and interferon pathways. |
| Q49644946 | Salmonella Vaccines: Conduits for Protective Antigens |
| Q35059006 | Salmonella synthesizing 1-dephosphorylated [corrected] lipopolysaccharide exhibits low endotoxic activity while retaining its immunogenicity. |
| Q36933812 | Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist. |
| Q33553810 | Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A. |
| Q54787200 | Selective induction of the Notch ligand Jagged-1 in macrophages by soluble egg antigen from Schistosoma mansoni involves ERK signalling. |
| Q96137394 | Self-healing microcapsules synergetically modulate immunization microenvironments for potent cancer vaccination |
| Q36421502 | Sensing gram-negative bacterial lipopolysaccharides: a human disease determinant? |
| Q31138173 | Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy |
| Q64941421 | Silencing SOCS1 via Liposome-Packed siRNA Sustains TLR4-Ligand Adjuvant. |
| Q38844616 | Small-Molecule Carbohydrate-Based Immunostimulants. |
| Q38830870 | Solid-in-oil nanodispersions for transdermal drug delivery systems. |
| Q38443427 | Spaceflight impairs antigen-specific tolerance induction in vivo and increases inflammatory cytokines. |
| Q37045125 | Specific Dioscorea Phytoextracts Enhance Potency of TCL-Loaded DC-Based Cancer Vaccines |
| Q55024241 | Specific features of human monocytes activation by monophosphoryl lipid A. |
| Q39539750 | Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides |
| Q33825974 | Substitution of the Bordetella pertussis lipid A phosphate groups with glucosamine is required for robust NF-kappaB activation and release of proinflammatory cytokines in cells expressing human but not murine Toll-like receptor 4-MD-2-CD14 |
| Q50041674 | Subversion of innate and adaptive immune activation induced by structurally modified lipopolysaccharide from Salmonella typhimurium. |
| Q60047402 | Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice |
| Q28513770 | Suppression of LPS-induced TNF-alpha production in macrophages by cAMP is mediated by PKA-AKAP95-p105 |
| Q38072067 | Synthetic adjuvants for vaccine formulations: phytol derivatives |
| Q54967965 | Synthetic glycan-based TLR4 agonists targeting caspase-4/11 for the development of adjuvants and immunotherapeutics. |
| Q38020881 | Systematic identification of small molecule adjuvants |
| Q40823419 | Systemic Activation of TLR3-Dependent TRIF Signaling Confers Host Defense against Gram-Negative Bacteria in the Intestine |
| Q26830374 | Systems biology applied to vaccine and immunotherapy development |
| Q56897738 | TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines |
| Q35755142 | TLR signaling that induces weak inflammatory response and SHIP1 enhances osteogenic functions |
| Q35091594 | TLR2, TLR4 and CD14 recognize venom-associated molecular patterns from Tityus serrulatus to induce macrophage-derived inflammatory mediators |
| Q91645553 | TLR4 Agonist Monophosphoryl Lipid A Alleviated Radiation-Induced Intestinal Injury |
| Q43603547 | TLR4 agonists as vaccine adjuvants: a chemist's perspective |
| Q27322386 | TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes |
| Q42131157 | TLR4 ligands augment antigen-specific CD8+ T lymphocyte responses elicited by a viral vaccine vector |
| Q33807405 | TLR4 ligands lipopolysaccharide and monophosphoryl lipid a differentially regulate effector and memory CD8+ T Cell differentiation. |
| Q37259689 | TLR4 signaling via MyD88 and TRIF differentially shape the CD4+ T cell response to Porphyromonas gingivalis hemagglutinin B |
| Q89551303 | TLR4-Targeting Therapeutics: Structural Basis and Computer-Aided Drug Discovery Approaches |
| Q37039006 | TLR4-mediated activation of dendritic cells by the heat shock protein DnaK from Francisella tularensis. |
| Q45988450 | TLR4-mediated pro-inflammatory dendritic cell differentiation in humans requires the combined action of MyD88 and TRIF. |
| Q92123390 | TLRs in pulmonary diseases |
| Q34607160 | TRIF is required for TLR4 mediated adjuvant effects on T cell clonal expansion |
| Q38830698 | TRIF-dependent TLR signaling, its functions in host defense and inflammation, and its potential as a therapeutic target |
| Q40051350 | TRIM32-TAX1BP1-dependent selective autophagic degradation of TRIF negatively regulates TLR3/4-mediated innate immune responses |
| Q26992220 | Targeting Toll-like receptors with small molecule agents |
| Q37727910 | Targeting Toll-like receptors: emerging therapeutics? |
| Q37896347 | Targeting of Toll-like receptors: a decade of progress in combating infectious diseases |
| Q37628867 | The ABC of clinical and experimental adjuvants--a brief overview |
| Q35998757 | The Carbomer-Lecithin Adjuvant Adjuplex Has Potent Immunoactivating Properties and Elicits Protective Adaptive Immunity against Influenza Virus Challenge in Mice. |
| Q27675591 | The Crystal Structure of Human Soluble CD14 Reveals a Bent Solenoid with a Hydrophobic Amino-Terminal Pocket |
| Q35838023 | The Immune Response to Trypanosoma cruzi: Role of Toll-Like Receptors and Perspectives for Vaccine Development |
| Q47147061 | The Role of Carbohydrates in the Lipopolysaccharide (LPS)/Toll-Like Receptor 4 (TLR4) Signalling |
| Q55425891 | The Structure of the Lipid A from the Halophilic Bacterium Spiribacter salinus M19-40T. |
| Q53692340 | The TLR4 Agonist Monophosphoryl Lipid A Drives Broad Resistance to Infection via Dynamic Reprogramming of Macrophage Metabolism. |
| Q34445270 | The TLR4 D299G and T399I SNPs are constitutively active to up-regulate expression of Trif-dependent genes |
| Q38787350 | The TLR4-TRIF pathway can protect against the development of experimental allergic asthma |
| Q52597551 | The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer. |
| Q44221211 | The Toll-like receptor 1/2 agonists Pam(3) CSK(4) and human β-defensin-3 differentially induce interleukin-10 and nuclear factor-κB signalling patterns in human monocytes |
| Q28587156 | The attenuated inflammation of MPL is due to the lack of CD14-dependent tight dimerization of the TLR4/MD2 complex at the plasma membrane |
| Q42723939 | The cationic lipid, diC14 amidine, extends the adjuvant properties of aluminum salts through a TLR-4- and caspase-1-independent mechanism |
| Q50857612 | The combination of Pleurotus ferulae water extract and CpG-ODN enhances the immune responses and antitumor efficacy of HPV peptides pulsed dendritic cell-based vaccine. |
| Q30406147 | The cytokine network of acute HIV infection: a promising target for vaccines and therapy to reduce viral set-point? |
| Q37572673 | The immunobiology of toll-like receptor 4 agonists: from endotoxin tolerance to immunoadjuvants |
| Q37110369 | The inflammatory tissue microenvironment in IBD. |
| Q43574552 | The influence of molecular adjuvants in the cutaneous response to antigen after topical vaccination |
| Q52327759 | The innate immune response to ischemic injury: a multiscale modeling perspective. |
| Q34484467 | The lipid A phosphate position determines differential host Toll-like receptor 4 responses to phylogenetically related symbiotic and pathogenic bacteria. |
| Q45811531 | The molecular basis of the host response to lipopolysaccharide |
| Q42627924 | The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine |
| Q37530899 | The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents |
| Q30425111 | The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? |
| Q45344331 | The role of MyD88- and TRIF-dependent signaling in monophosphoryl lipid A-induced expansion and recruitment of innate immunocytes |
| Q89700559 | The role of TLRs in cervical cancer with HPV infection: a review |
| Q36968250 | The science of adjuvants |
| Q37404966 | The structural basis for endotoxin-induced allosteric regulation of the Toll-like receptor 4 (TLR4) innate immune receptor. |
| Q24316449 | The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex |
| Q42473672 | The yin and yang of human Beta-defensins in health and disease |
| Q35894347 | Therapeutic cancer vaccines: current status and moving forward |
| Q26863283 | Therapeutic cancer vaccines: past, present, and future |
| Q37497786 | Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. |
| Q37416211 | Toll gates to periodontal host modulation and vaccine therapy |
| Q40416131 | Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV. |
| Q35751039 | Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors |
| Q35182848 | Toll-like receptor 4 (TLR4) is essential for Hsp70-like protein 1 (HSP70L1) to activate dendritic cells and induce Th1 response |
| Q33693637 | Toll-like receptor 4 (TLR4) modulation by synthetic and natural compounds: an update. |
| Q35550677 | Toll-like receptor 4 activation in cancer progression and therapy |
| Q36687238 | Toll-like receptor 4 signaling in intracerebral hemorrhage-induced inflammation and injury |
| Q37018342 | Toll-like receptor 4 signaling is required for induction of gluconeogenic gene expression by palmitate in human hepatic carcinoma cells. |
| Q36583003 | Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology. |
| Q33918509 | Toll-like receptor agonists in cancer therapy |
| Q37853197 | Toll-like receptor modulators: a patent review (2006-2010). |
| Q38237640 | Toll-like receptors and prostate cancer |
| Q42575579 | Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses |
| Q26746644 | Toll-like receptors: the swiss army knife of immunity and vaccine development |
| Q93079712 | Total Synthesis of an Immunogenic Trehalose Phospholipid from Salmonella Typhi and Elucidation of Its sn-Regiochemistry by Mass Spectrometry |
| Q33784812 | Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins |
| Q36194849 | Trial Watch: Experimental Toll-like receptor agonists for cancer therapy |
| Q42969291 | Trial Watch: Toll-like receptor agonists for cancer therapy |
| Q57394699 | Trial Watch: Toll-like receptor agonists in cancer immunotherapy |
| Q33878578 | Trial Watch: Toll-like receptor agonists in oncological indications |
| Q36373370 | Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy |
| Q99552011 | Trial watch: IDO inhibitors in cancer therapy |
| Q37118201 | Twelve immunotherapy drugs that could cure cancers |
| Q35695840 | Type I interferon signaling contributes to the bias that Toll-like receptor 4 exhibits for signaling mediated by the adaptor protein TRIF. |
| Q36547133 | Understanding how lipopolysaccharide impacts CD4 T-cell immunity |
| Q37403499 | Vaccination against foot-and-mouth disease virus: strategies and effectiveness |
| Q34054427 | Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection |
| Q36168232 | Vaccine Adjuvants: Putting Innate Immunity to Work |
| Q37403484 | Vaccine adjuvants: scientific challenges and strategic initiatives |
| Q38806558 | Vaccine technologies: From whole organisms to rationally designed protein assemblies |
| Q35938624 | Vaccines against drug abuse |
| Q35193959 | Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections |
| Q35176899 | Vaccinomics: current findings, challenges and novel approaches for vaccine development |
Search more.